Open an account

Cardiff Oncology

CRDF · NASDAQ

$0.9315+$0.0458 (+5.17%)TodayMarket closed ·
Prev close $0.8857

About CRDF

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2004-07-27. The firm's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The firm's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.

Employees
31
Headquarters
San Diego, California
Listed
Jul 27, 2004
Sector
Health Care
Industry
Biotechnology
Website
cardiffoncology.com

CRDF key statistics

Market cap
72.47M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
470.62K
Volume
595.48K
Open price
$0.9062
High today
$0.98
Low today
$0.88
52 Week high
$3.31
52 Week low
$0.7566

Cardiff Oncology (CRDF) at a glance

Cardiff Oncology (CRDF) last traded at $0.9315, with a market cap of 72.47M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.88 and $0.98. The current price is 5.9% above the day's low and 4.9% below its high.

Volume so far is 595.48K shares, above the average of 470.62K shares a day.

Over the past year Cardiff Oncology has ranged from $0.7566 to $3.31, and now sits 7% of the way up that range.

Cardiff Oncology met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.14 per share against an estimate of -$0.1645.

The average analyst price target is $7.45, 699.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

40%of 5 analyst ratings say Buy
  • Buy40.0%
  • Hold60.0%
  • Sell0.0%
Price target · 7 analystsAvg $7.45
Low
$2.02
Now
$0.9315
High
$12.60

CRDF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 19.2% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.2754
  2. Q4 FY24: reported -$0.22 per share against an estimate of -$0.2465
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.19
  4. Q2 FY25: reported -$0.21 per share against an estimate of -$0.1964
  5. Q3 FY25: reported -$0.17 per share against an estimate of -$0.2087
  6. Q4 FY25: reported -$0.11 per share against an estimate of -$0.1918
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.1373
  8. Q2 FY26: reported -$0.14 per share against an estimate of -$0.1645

CRDF news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

  • Avi Kapoor

    Crude Oil Moves Lower; US Producer Prices Fall 0.3% In June

  • Avi Kapoor

    Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views

  • Vandana Singh

    Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense

  • Press releaseGlobe Newswire

    Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

  • Press releaseGlobe Newswire

    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

  • A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts

Similar companies

Companies in the same industry as Cardiff Oncology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.